Koji Pharmaceutical Industry-B (02171.HK) plans to repurchase up to 1% of the total number of issued shares.

The Zhitong Financial News APP reported that Keji Pharmaceutical -B (02171.HK) has announced that the company's board of directors has approved a share buyback plan. Starting from May 8, 2025, within 150 Hong Kong trading days, in accordance with the share buyback authorization for 2024 and (if applicable) the share buyback authorization approved by the shareholders at the annual general meeting to be held on May 22, 2025, the company will repurchase on the open market up to 1% of the total issued shares of the company.